

November 9, 2017

## **Creoptix announces entering UK market with Mologic as first customer and providing new research avenues for Mologic's Centre for Advanced Rapid Diagnostics ("CARD")**

Creoptix AG proudly announces the entering of the attractive UK market with Mologic as its first UK-based customer. Creoptix' WAVEdelta system will be used at Mologic's Centre for Advanced Rapid Diagnostics ("CARD") in support of their ambitious assay development program. CARD is supported by a grant from the Bill & Melinda Gates Foundation and aims to develop simple, rapid, ultra-sensitive diagnostic test technology for the detection of protein biomarkers at the point-of-care in developing countries.

Creoptix Chief Technology Officer, Kaspar Cottier, said, "We are very proud of supporting Mologic's CARD project with our Creoptix WAVEdelta system that we launched this year. Based on its high sensitivity and crude sample robustness, we enable Mologic to perform kinetic characterization of antibodies in crude body fluids like serum or plasma at a data quality that has not been seen before. It is very satisfying to see how our technology provides data enabling a selection for the most optimal diagnostic reagents." Based on a proprietary sensor technology and disposable, robust microfluidics, the Creoptix WAVEdelta combines very high sensitivity with broadest sample compatibility. Undiluted samples including serum, plasma and cell supernatants can be run on the system which is of particular interest to customers developing antibody therapeutics and diagnostic reagents. "We liked this project with Mologic from the very beginning." said Creoptix Chief Executive Officer, Matyas Vegh, "analyzing kinetics in crude plasma is very challenging but has great potential as reagents and drugs are used in complex environments and not in a test tube with a clear solution."

Dr James Schouten, Lead Scientist in Mologic's CARD team, said "Understanding the dynamics of our detection reagents in complex matrices presents a big challenge when developing new assay platforms, particularly as we advance the limits of sensitivity with novel amplification technologies. The WAVEdelta system opens up new exciting opportunities for the project by giving us a real-time view of these interactions. The impressive detection range and versatility of the system will be a huge asset as the project progresses"

### **About Creoptix and Creoptix WAVE Technology [www.creoptix.com](http://www.creoptix.com)**

Creoptix AG is a privately-held company founded in 2009 and headquartered in Wädenswil, near Zurich, Switzerland. Creoptix focuses on the development of next generation instruments for the high-sensitivity kinetics and affinity analysis of label-free molecular interactions based on innovative, proprietary technology. Based on proprietary technology, the Creoptix WAVE provides exceptionally high sensitivity and resolution at even very low signal levels, fastest kinetics and a compatibility with crude samples like undiluted serum or plasma, cell supernatant, crude membrane extracts or large particles like viruses, VLPs, liposomes etc.

To request further information about Creoptix™ WAVE, please feel free to contact us by e-mail at [info@creoptix.com](mailto:info@creoptix.com) or phone: +41 44 533 26 60.

Creoptix AG, Einsiedlerstrasse 34, 8820 Wädenswil, Switzerland

**About Mologic** <https://mologic.co.uk/>

Mologic Ltd develops powerful, personalised diagnostics to improve the lives of patients. With a scientific team expert in translating science into practical solutions, the Company delivers technology where it is needed, to improve patient care and quality of life, breaking new ground in exciting fields of research. Mologic is focused on collaboration, partnerships and diversity and its innovative approach has generated an advanced portfolio of accurate and reliable point of care diagnostic tools for a variety of conditions, including COPD, diabetes, sepsis, UTIs, malignancies, inflammatory and respiratory conditions, and renal disease.

Led by co-founders Paul Davis, CSO, and Mark Davis, CEO, the Company's broad range of skills and experience covers services from innovation to manufacture, including molecular engineering, assay and reagent development, clinical evaluation, antibodies, research and IP. Mologic's low-volume manufacturing facility (ISO13485 certified) enables the business to take on almost any project challenge, irrespective of size, complexity or stage. Through professional partnerships, products have achieved high volume manufacturing, distribution and regulatory support globally.

Mologic's interests extend beyond human healthcare, with active programs in agricultural diagnostics, large animal studies and vaccine innovation, successfully translating their advances in patient technology to other sectors.